Rioprostil and Ranitidine in the Prevention of Duodenal Ulcer Relapse

Abstract

Rampal P, Raillat A, Viteau J-M, Slama J-L, Lavignolle A, Bedenne L, Veyres B, Toulet J, Vray M, Prunieras F. Rioprostil and ranitidine in the prevention of duodenal ulcer relapse. Scand J Gastroenterol 1989, 24(suppl 164), 146-151

One hundred and ninety duodenal ulcer patients who had relief of pain and endo-scopically proven ulcer healing after a short treatment period are allocated at random to double-blind maintenance treatment with a synthetic dehydroprostaglandin-E₁, rioprostil, 300 μg, or ranitidine, 150 mg, at bedtime for 6 months. Patients are monitored every two months and examined by endoscopy after six months of treatment, or more often if warranted. The cumulative relapse rate in the rioprostil group at six months is 32% (25/78) us. 28% (20/72) in the ranitidine group. This difference is not significant. The percentage of side effects observed is 17% in the rioprostil group us. 5% in the ranitidine group, but discontinuation of treatment is observed with the same frequency in the two groups.

Key Words:

• Clinical trials
• drug therapy
• duodenal ulcer
• H₂-blocker
• prostaglandin analogues
• prostaglandin E
• synthetic